<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094610</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0005-07</org_study_id>
    <nct_id>NCT04094610</nct_id>
  </id_info>
  <brief_title>A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations</brief_title>
  <official_title>A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib&#xD;
      in pediatric and young adult subjects with advanced or metastatic malignancies harboring&#xD;
      anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1),&#xD;
      or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to&#xD;
      estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the&#xD;
      Pediatric Recommended Phase 2 Dose (RP2D).&#xD;
&#xD;
      Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric subjects with&#xD;
      advanced or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment of subjects into Phase 1 will proceed concurrently by age as follows:&#xD;
&#xD;
        -  Subjects &lt;12 years old will initially be enrolled in the Phase 1 part to determine the&#xD;
           pediatric RP2D for this age group; once the pediatric RP2D is determined, subjects age&#xD;
           &lt;12 years old may be enrolled into the Phase 2 part of the study.&#xD;
&#xD;
        -  Subjects 12 to 25 years old will be directly enrolled into the Phase 2 part concurrent&#xD;
           with Phase 1 enrollment.&#xD;
&#xD;
      Phase 1:&#xD;
&#xD;
      Approximately 12 pediatric subjects with locally advanced or metastatic solid tumors,&#xD;
      including a primary central nervous system (CNS) tumor, or anaplastic large cell lymphoma&#xD;
      (ALCL), with disease progression or who are non-responsive or intolerant to available&#xD;
      therapies and for which no standard or available curative therapy exists.&#xD;
&#xD;
      Phase 2:&#xD;
&#xD;
      Subjects will be enrolled in one of 3 cohorts as follows:&#xD;
&#xD;
      Cohort 1: approximately 10-20 subjects with solid tumors characterized by NTRK fusion, TRK&#xD;
      tyrosine kinase inhibitor (TKI)-naïve, and centrally confirmed measurable disease at&#xD;
      baseline.&#xD;
&#xD;
      Cohort 2: approximately 23 subjects with solid tumors characterized by NTRK fusion, TRK&#xD;
      TKI-pretreated, and centrally confirmed measurable disease at baseline.&#xD;
&#xD;
      Cohort 3: approximately 20 subjects with solid tumors or ALCL characterized by other&#xD;
      ALK/ROS1/NTRK alterations or NTRK fusions without centrally confirmed measurable disease not&#xD;
      otherwise eligible for Cohort 1 or 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>Within 28 days of the first repotrectinib dose</time_frame>
    <description>Define the dose limiting toxicities (DLTs) (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)</measure>
    <time_frame>Within 28 days of the last patient dosed in escalation</time_frame>
    <description>To determine the pediatric RP2D (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) (Phase 2)</measure>
    <time_frame>Two to three years after first dose of repotrectinib</time_frame>
    <description>To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) (Phase 1)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the overall response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) (Phase 1 and Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the CBR of repotrectinib (TPX-0005) (Phase 1 and Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) (Phase 1 and Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the TTR of reprotrectinib (TPX-005) (Phase 1 and Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Phase 1 and Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the DOR of repotrectinib (TPX-0005) (Phase 1 and Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response rate (IC-ORR) (Phase 1 and Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the IC-ORR of repotrectinib (TPX-005) (Phase 1 and Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System Progression-Free Survival (CNS-PFS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>CNS-PFS in subjects with measurable brain metastases (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the PFS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the OS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of repotrectinib in plasma (Cmax)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)</time_frame>
    <description>To determine the Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve of repotrectinib in plasma (AUC)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)</time_frame>
    <description>To determine the AUC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Primary CNS Tumors</condition>
  <arm_group>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1&#xD;
Oral repotrectinib (TPX-0005):&#xD;
Safety and tolerability at different dose levels&#xD;
Phase 2&#xD;
Oral repotrectinib (TPX-0005): 3 cohorts&#xD;
Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ALK/ROS1/NTRK alterations or fusions in tumors and ALCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral repotrectinib (TPX-0005)</intervention_name>
    <description>Oral repotrectinib (TPX-0005)</description>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <other_name>Oral repotrectinib (TPX-0005) capsules</other_name>
    <other_name>Oral repotrectinib (TPX-0005) oral suspension</other_name>
    <other_name>repotrectinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Documented genetic ALK, ROS1, or NTRK1-3 alteration (point mutation, fusion,&#xD;
             amplification) as identified by local testing in a Clinical Laboratory Improvement&#xD;
             Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab&#xD;
             outside the United States (US) is required.&#xD;
&#xD;
          2. Phase 1: Age &lt;12 years; Phase 2: Age 12- 25 years&#xD;
&#xD;
          3. Prior cytotoxic chemotherapy is allowed.&#xD;
&#xD;
          4. Prior immunotherapy is allowed.&#xD;
&#xD;
          5. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer&#xD;
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.&#xD;
&#xD;
          6. All subjects must have measurable disease by RECIST v1.1 or Response Assessment in&#xD;
             Neuro-Oncology Criteria (RANO) criteria at time of enrollment.&#xD;
&#xD;
          7. Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a&#xD;
             stable or decreasing dose of steroids for at least 14 days prior to enrollment.&#xD;
&#xD;
          8. Subjects must have a Lansky (&lt; 16 years) or Karnofsky (≥ 16 years) score of at least&#xD;
             50.&#xD;
&#xD;
          9. Life expectancy greater than or equal to 12 weeks.&#xD;
&#xD;
         10. Adequate hematologic, renal and hepatic function.&#xD;
&#xD;
        Phase 2 Inclusion Criteria:&#xD;
&#xD;
          1. Cohort Specific Inclusion Criteria:&#xD;
&#xD;
               -  Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors&#xD;
                  (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI&#xD;
                  naïve;&#xD;
&#xD;
               -  Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS&#xD;
                  tumors), that are TRK TKI pre-treated;&#xD;
&#xD;
               -  Cohort 3: subjects with tumors or ALCL characterized by other ALK/ROS1/NTRK&#xD;
                  alterations or NTRK fusions without centrally confirmed measurable disease or not&#xD;
                  otherwise eligible for Cohort 1 or 2.&#xD;
&#xD;
          2. Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by&#xD;
             BICR prior to enrollment.&#xD;
&#xD;
        Key Exclusion Criteria (Phase 1 and Phase 2):&#xD;
&#xD;
          1. Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow&#xD;
             aspiration only.&#xD;
&#xD;
          2. Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central&#xD;
             venous access (Broviac, Mediport, etc.) placement does not meet criteria for major&#xD;
             surgery.&#xD;
&#xD;
          3. Known active infections (bacterial, fungal, viral including HIV positivity).&#xD;
&#xD;
          4. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut&#xD;
             syndrome) or other malabsorption syndromes that would impact drug absorption.&#xD;
&#xD;
          5. Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting corrected QT interval (ECG interval measured from the onset of the&#xD;
                  QRS complex to the end of the T wave) for heart rate (QTc) &gt; 480 msec obtained&#xD;
                  from three ECGs, using the screening clinic ECG machine-derived QTc value&#xD;
&#xD;
               -  Any clinically important abnormalities in rhythm, conduction, or morphology of&#xD;
                  resting ECG (e.g., complete left bundle branch block, third degree heart block,&#xD;
                  second degree heart block, PR interval &gt; 250 msec)&#xD;
&#xD;
               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events such as heart failure, congenital long QT syndrome, family history of long&#xD;
                  QT syndrome, or any concomitant medication known to prolong the QT interval&#xD;
&#xD;
          6. Peripheral neuropathy of CTCAE ≥grade 2.&#xD;
&#xD;
          7. Subjects being treated with or anticipating the need for treatment with strong CYP3A4&#xD;
             inhibitors or inducers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Zimmerman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachary Zimmerman, M.D.</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leo Mascarenhas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noah Federman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margaret Macy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Aguilar-Bonilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stanley Chaleff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven G. DuBois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew S. Cluster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Moerdler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tara O'Donohue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matteo Trucco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital at Penn State Health Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valerie I. Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Theodore Laetsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center, Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tanya Watt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. David Ziegler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Geoffrey McCowage</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Tim Hassall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Nicholas Gottardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Sunil Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Hyoung Jin Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Chuhl Joo Lyu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Kyung-Nam Koh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Keon Hee Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Allen Yeoh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Shui Yen Soh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>100225</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Shiann-Tarng Jou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr. Yen-Lin Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>ROS1</keyword>
  <keyword>NTRK1-3</keyword>
  <keyword>Primary CNS tumor</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>metastatic solid tumor</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>sarcoma</keyword>
  <keyword>infantile fibrosarcoma</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>soft tissue schwannoma</keyword>
  <keyword>solitary fibrous tumor</keyword>
  <keyword>glioma</keyword>
  <keyword>inflammatory myofibroblastic tumor</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

